JNTU B.Pharmacy III PHARMACEUTICAL QUALITY ASSURANCE Previous Question Paper (July - 2021 - R17)

Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. The key elements and tools are as follows:

The fundamental elements of QbD include:

• Quality Target Product Profile (QTPP): A prospective summary of the quality characteristics of a drug product that ideally will be achieved to ensure the desired quality, taking into account safety and efficacy.
• Critical Quality Attributes (CQAs): Physical, chemical, biological, or microbiological properties or characteristics that should be within an appropriate limit, range, or distribution to ensure the desired product quality.
• Critical Process Parameters (CPPs): Process parameters whose variability has an impact on a CQA and therefore should be monitored or controlled to ensure the process produces the desired quality.
• Design Space: The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality.
• Control Strategy: A planned set of controls, derived from current product and process understanding, that assures process performance and product quality.

The primary tools used to implement QbD are:

• Risk Assessment: Tools like Failure Mode and Effects Analysis (FMEA) or Ishikawa (fishbone) diagrams are used to identify potential sources of variability and prioritize risks to product quality.
• Design of Experiments (DoE): A structured, organized method for determining the relationship between factors affecting a process and the output of that process. It allows for the identification of interactions between variables and the establishment of the design space.
• Process Analytical Technology (PAT): A system for designing, analyzing, and controlling manufacturing through timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes.
• Knowledge Management: Systematic approaches to acquiring, analyzing, storing, and disseminating information related to products, manufacturing processes, and components to support continuous improvement throughout the product lifecycle.

The International Council for Harmonisation (ICH) Q1 series guidelines provide a standardized framework for stability testing of new drug substances and products to ensure that the quality, safety, and efficacy of pharmaceutical products are maintained throughout their shelf life. These guidelines define the requirements for data submission in registration applications across ICH regions.

Key components of the ICH stability testing guidelines include:

• Stability Testing of New Drug Substances and Products (Q1A): This guideline specifies the stress testing, selection of batches, container closure systems, and testing frequency. It mandates testing under various climatic conditions, categorized by zones, to determine the retest period or shelf life.
• Photostability Testing (Q1B): This requires exposure of the drug substance and product to light to ensure that light-induced degradation does not occur. It involves forced degradation studies using a light source that emits both UV and visible light.
• Climatic Zones and Conditions (Q1C-Q1F): The guidelines define standard long-term, intermediate, and accelerated storage conditions. For example, the general case for accelerated stability testing is 40°C ± 2°C / 75% RH ± 5% RH for a period of 6 months.
• Bracketing and Matrixing (Q1D): These statistical designs allow for reduced testing frequency. Bracketing involves testing only the extremes of certain design factors (e.g., strength or container size), while matrixing involves testing a subset of the total number of samples at specified time points.
• Evaluation of Stability Data (Q1E): This provides guidance on how to analyze stability data, including the use of statistical methods to determine the shelf life or retest period based on the degradation trends observed.
• Stability Data Package for Registration (Q1F): This outlines the specific data requirements for marketing authorization applications, ensuring that the stability profile is robust enough to support the proposed storage conditions and expiration dating.

By adhering to these guidelines, manufacturers ensure global consistency in stability data, facilitating the mutual recognition of test results and accelerating the regulatory approval process for pharmaceutical products.